# Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)

> **NCT04317092** · PHASE2 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 402 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Tocilizumab Injection

## Key facts

- **NCT ID:** NCT04317092
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-19
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04317092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04317092, "Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04317092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*